This potential probiotic has considerable “protective” anti-cancer properties comparable to the already in use drugs cetuximab and trastuzumab and is able to concomitantly down regulate EGFR, HER-2 and PTGS-2 (COX-2) onco-markers and significantly ameliorate disease activity index, restore colon length, inhibit the increase in tumor incidence and prevent the progress of tumors to higher stages and grades. The gene discussed is EGFR; the disease is cancer.